Background-Although statins are reported to have a cardioprotective effect, their immediate direct influence on ischemia-reperfusion injury and the underlying mechanisms remain obscure. We investigated these issues an in vivo canine model. Methods and Results-Dogs were subjected to coronary occlusion (90 minutes) and reperfusion (6 hours) immediately after injection of pravastatin (0.2, 2, or 10 mg/kg), pitavastatin (0.01, 0.1, or 0.5 mg/kg), or cerivastatin (0.5, 5, or 50 g/kg). Then myocardial phosphatidylinositol 3-kinase (PI3-K) and 5Ј-nucleotidase activities were measured, as well as infarct size. After 15 minutes of reperfusion, pravastatin caused dose-dependent activation of Akt and ecto-5Ј-nucleotidase in the ischemic zone, and the effect was significant at higher doses. Pitavastatin also significantly increased these activities, and its optimal dose was within the clinical range, whereas cerivastatin caused activation at the lowest dose tested. In all cases, both Akt and ecto-5Ј-nucleotidase showed activation in parallel, and this activation was completely abolished by wortmannin, a PI3-K inhibitor. The magnitude of the infarct-limiting effect paralleled the increase in Akt and ecto-5Ј-nucleotidase activity and was blunted by administration of wortmannin, ␣,␤-methyleneadenosine-5Ј-diphosphate, or 8-sulfophenyltheophylline during reperfusion. Both collateral flow and the area at risk were comparable for all groups. Conclusions-Activation of ecto-5Ј-nucleotidase after ischemia by PI3-K activation may be crucial for immediate infarct-size limitation by statins. There seems to be an optimal dose for each statin that is independent of its clinical cholesterol-lowering effect.
T he 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) block the biosynthesis of cholesterol 1 and are widely used clinically to decrease serum cholesterol levels. Recent studies have focused on the pleiotropic effects of either hydrophilic 2, 3 or hydrophobic 4, 5 statins, which are independent of their cholesterollowering effect. 2 , 3 , 5 Protection against ischemiareperfusion injury is one of them, which is particularly evident after 12 hours. 6, 7 In addition, some studies showed that statins activate the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway within 1 hour, 8, 9 as well as activating endothelial nitric oxide synthase (eNOS), 9, 10 to cause immediate infarct limitation. 9 On the other hand, other studies revealed that statins also acutely activate ecto-5Ј-nucleotidase, 11 which produces the endogenous cardioprotective substance adenosine, 12 especially in response to certain stresses. 13 Ecto-5Ј-nucleotidase can act only when localized on the cell membrane, 13 and the density of this enzyme on the membrane regulates its activity. 11, 14 Endocytotic turnover of ecto-5Ј-nucleotidase (5Ј-nucleotidase localized on the cell surface) is inhibited by PI3-K activation, 14 which subsequently increases total 5Ј-nucleotidase activity within a period as short as 10 minutes. 14 Therefore, we hypothesized that an increase of ecto-5Ј-nucleotidase activity might be critical for early cardioprotec-tion mediated by statins and might be associated with rapid activation of PI3-K.
Here we used a dog model to determine whether 3 statins with different water solubilities (pravastatin, pitavastatin, and cerivastatin) could acutely limit infarct size, as well as whether adenosine and PI3-K were involved in the underlying mechanism.
Methods
All procedures were performed in conformity with the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, 1996 revision) and were approved by the Osaka University Committee for Laboratory Animal Use. Pravastatin, pitavastatin, and cerivastatin were obtained from Sankyo, Kowa, and Takeda Pharmaceuticals, respectively. The other drugs were obtained from Sigma.
Instrumentation
Beagle dogs weighing 8 to 13 kg were anesthetized and connected to an extracorporeal bypass tube as described previously. 15, 16 In all experiments, the average baseline values of mean aortic blood pressure (ABP), heart rate (HR), and arterial blood PO 2 were 102Ϯ2.2 mm Hg, 129Ϯ2.5 min Ϫ1 , and 109Ϯ4.1 mm Hg, respectively. Both ABP and HR were measured continuously during the study.
Experimental Protocols

Protocol 1: Measurement of Infarct Size and Myocardial Collateral Blood Flow
After hemodynamic stabilization, we infused pravastatin (0.2, 2, or 10 mg/kg), pitavastatin (0.01, 0.1, or 0.5 mg/kg), cerivastatin (0.5, 5, or 50 g/kg) or saline intravenously for 10 minutes before 90 minutes of sustained ischemia, which was followed by 6 hours of reperfusion (nϭ9 to 13 each). Some groups also received intracoronary administration of a selective ecto-5Ј-nucleotidase inhibitor (␣,␤-methyleneadenosine-5Ј-diphosphate [AMP-CP; 80 g · kg Ϫ1 · min Ϫ1 ); a nonselective adenosine receptor antagonist (8-sulfophenyltheophylline [8-SPT; 50 g · kg Ϫ1 · min Ϫ1 ]); or a selective PI3-K inhibitor (wortmannin [1.5 g · kg Ϫ1 · min Ϫ1 ]) between 5 minutes before and 60 minutes after reperfusion. We measured infarct size and regional myocardial collateral blood flow during 90 minutes of ischemia as described previously. 15 We have already confirmed in the same model that the doses of AMP-CP, 17 8-SPT, 17, 18 or wortmannin 19 used in this study were appropriate to block ecto-5Ј-nucleotidase, the adenosine receptors, or PI3-K, respectively. Figure 1 shows the details of this protocol, and the Table lists all of the groups studied.
Protocol 2: Myocardial Enzyme Assays
Another 54 dogs underwent a procedure identical to that of some groups from protocol 1 and were studied for enzyme assays (nϭ3 or 4 each). In this protocol, not only wortmannin (1.5 g · kg Ϫ1 · min Ϫ1 ) but also LY294002 (60 g · kg Ϫ1 · min Ϫ1 ) was used as another selective PI3-K inhibitor. After 15 minutes of reperfusion, a myocardial tissue sample was obtained from the ischemic border zone to ensure evaluation of viable ischemic myocardium and was used for the measurement of PI3-K and ecto-/endo-5Ј-nucleotidase activity. The myocardial tissue was rapidly frozen in LN 2 and stored at Ϫ80°C. Measurement of PI3-K and 5Ј-nucleotidase activity was done as reported previously 15, 19 with minor modifications.
Criteria for Exclusion
To ensure that all of the animals included in analysis were healthy and were exposed to a similar extent of ischemia, the exclusion criteria reported previously 16 for hemodynamics, excessive collateral flow, and lethal arrhythmia were adopted.
Statistical Analysis
Results were expressed as meanϮSEM, and the number of animals or experiments is shown as n. Statistical analysis was performed by ANOVA with a modified Bonferroni post hoc test, and significance was defined at PϽ0.05.
Results
Mortality and Exclusions in Protocol 1
Among 222 dogs used in protocols 1, 56 dogs met the exclusion criteria of ventricular fibrillation or excessive myocardial collateral blood flow (Ͼ15 mL · 100 g Ϫ1 · min Ϫ1 ). Therefore, 166 dogs completed these protocols satisfactorily and were included in the data analysis (Table) .
Changes in Hemodynamic Parameters, Risk Area, and Collateral Blood Flow in Protocol 1
The changes in ABP and HR were comparable among all groups throughout the protocol (data not shown), and both the area at risk and collateral blood flow were also comparable (Table) . Figure 2 shows infarct size in the groups of protocol 1. Pravastatin (0.2, 2, and 10 mg/kg) dose-dependently reduced the infarct size (29.5Ϯ3.5%, 22.5Ϯ4.0%, and 18.8Ϯ3.4%, respectively) compared with that in the control group (39.8Ϯ3.6%), and the difference was significant at 2 mg/kg or more. Pitavastatin (0.01, 0.1, and 0.5 mg/kg) also reduced infarct size (32.9Ϯ3.9%, 23.6Ϯ3.8%, and 31.4Ϯ3.9%, respectively), although the optimal dose was 0.1 mg/kg (the only dose that produced a significant difference). Although cerivastatin (0.5, 5, and 50 g/kg) caused infarct limitation (26.2Ϯ3.2%, 32.1Ϯ5.3%, and 37.1Ϯ4.4%, respectively), it was significant at the lowest dose only, and the effect was weaker at higher doses. Furthermore, cotreatment with AMP-CP, 8-SPT, or wortmannin between 5 minutes before and 60 minutes after reperfusion abrogated the infarct-limiting effect of pravastatin (39.9Ϯ4.0%, 42.6Ϯ4.0%, or 38.6Ϯ3.6%, respectively), pitavastatin (40.4Ϯ3.1%, 39.4Ϯ3.6%, or 39.1Ϯ3.1%, respectively), and cerivastatin (41.1Ϯ3.7%, 42.1Ϯ3.9%, or 40.4Ϯ4.0%, respectively), although these drugs per se did not affect infarct size (42.7Ϯ4.5%, 40.3Ϯ3.5%, or 42.7Ϯ4.5%, respectively). Figure 3 shows the activity of ecto-/endo-5Ј-nucleotidase in protocol 2. Sustained ischemia for 90 minutes and 15 minutes of subsequent reperfusion did not significantly change the activity of ecto-5Ј-nucleotidase (41.0Ϯ5.7 versus 33.2Ϯ1.2 nmol · mg protein Ϫ1 · min Ϫ1 at baseline). Preischemic treat- Figure 4 shows the activity of PI3-K in protocol 2. Sustained ischemia for 90 minutes and subsequent reperfusion for 15 minutes did not change PI3-K activity significantly (123Ϯ23% versus 100Ϯ14% at baseline). Preischemic treatment with pravastatin caused dose-dependent and acute activation of ecto-5Ј-nucleotidase in the ischemic zone, which was significant at the highest dose (249Ϯ44% at 10 mg/kg, PϽ0.05 versus control). Pitavastatin also caused significant activation at its medium dose (218Ϯ34% at 0.1 mg/kg, PϽ0.05 versus control), whereas cerivastatin caused activation at the lowest dose (214Ϯ31% at 0.5 g/kg, PϽ0.05 versus control). We confirmed that all of these increases were also blocked by wortmannin (81Ϯ38% for pravastatin, 77Ϯ32% for pitavastatin, and 76Ϯ39% for cerivastatin) or LY294002 (69Ϯ23% for pravastatin, 70Ϯ27% for pitavastatin, and 68Ϯ21% for cerivastatin).
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Discussion
The present study demonstrates that several statins provide immediate infarct limitation of different magnitudes and at different optimal doses. Our results also suggest that activation of ecto-5Ј-nucleotidase through the activation of PI3-K after ischemia was involved in this cardioprotective mechanism of statins.
Cholesterol-Lowering Effects and Immediate Infarct Limitation of Statins
In this study, we set the doses of statins in line with their clinical cholesterol-lowering properties. In Japan, the standard clinical doses to obtain a 20% to 30% reduction of total plasma cholesterol levels were 10 mg/d for pravastatin, 2 mg/d for pitavastatin, and 0.15 mg/d for cerivastatin. Our preliminary trials in the same dog model revealed that a single intravenous injection of 0.2 mg/kg pravastatin, 0.1 mg/kg pitavastatin, or 5 g/kg cerivastatin approximated the clinical cholesterol-lowering dose based on the maximal plasma concentration of each statin (data not shown). Because (1) the maximal infarct limitation was achieved by a higher dose of pravastatin than the clinical dose, whereas the dose was similar to the clinical dose for pitavastatin and lower for cerivastatin, and (2) these statins showed early cardioprotection within 2 hours of administration in this model, it is strongly suggested that the magnitude of immediate infarct limitation by each statin is not correlated with its cholesterol-lowering effect.
Existence of Optimal Cardioprotective Doses for Each Statin
In the present report, we have directly shown that pitavastatin has the optimal dose to reduce infarct size. Obviously, there is also an optimal dose for cerivastatin under the lowest dose we tried, because infarct size with far lower doses of cerivastatin near zero will converge with those of control levels. In the case of pravastatin, our additional experiment, within the limitation with regard to the total amount of the drug we could obtain, showed that 100 mg/kg pravastatin administered in the same manner as in protocol 1 exerted similar (but a slightly weaker) magnitude of reducing infarct size (20.9Ϯ4.5%, nϭ5) compared with that achieved with 10 mg/kg of this agent. Although we could not show direct evidence in this case, it would at least not deny the possibility for the existence of an optimal dose of pravastatin. Furthermore, other reports also showed the existence of an optimal dose of atorvastatin for infarct limitation 9 or of simvastatin for PI3-K activation. 8 Taken together, the existence of optimal doses should be ubiquitous among all (or at least all hydrophobic) statins.
Although direct exhibition of the reason for this phenomenon remains unclear in this study, there might be some reasons to regulate the respective optimal windows for each statin, eg, differences in the ability to attenuate inflammatory response 20 or in the potency of direct absorption into cellular membrane to modulate intracellular signaling systems. In addition, our present finding that infarct limitation completely paralleled the activation of PI3-K leads us to hypothesize that the lesser effects by the higher doses of statins should be regulated upstream of PI3-K. One possibility is that all hydrophobic statins can dose-dependently activate apoptosisrelated signals, 21 which might also explain the wide range of higher cardioprotective doses for pravastatin specifically. Finally, additional studies will need to be performed to obtain direct evidence.
Cardioprotective Mechanisms
Our observations that (1) activation of PI3-K and ecto-5Ј-nucleotidase was coincident with a substantial limitation of infarct size, (2) either wortmannin or AMP-CP abolished cardioprotection by all 3 statins, (3) different PI3-K inhibitors at reperfusion actually inhibited PI3-K activity ( Figure 4 ) and subsequently reduced ecto-5Ј-nucleotidase activity ( Figure  3) , and (4) our preliminary documentation that PI3-K inhibition by either wortmannin of LY294002 before ischemia did not abolish the infarct limitation by statins in the present study (nϭ4 or 5, data not shown), together suggest that infarct limitation in this model was linked to the activation of PI3-K during reperfusion, not before ischemia, followed by ecto-5Ј-nucleotidase activation.
In this study, we did not determine the exact mechanism of how PI3-K activates ecto-5Ј-nucleotidase. Although we have previously reported that phosphorylation of ecto-5Ј-nucleotidase might be crucial, 22 other mechanisms may also be involved, such as endocytotic turnover. 17 In addition, although we did not evaluate real-time regional myocardial production of adenosine in each group, treatment with a potent adenosine receptor antagonist (8-SPT) during reperfusion also blunted infarct limitation by statins along with the inhibition of ecto-5Ј-nucleotidase, further suggesting that cardioprotection against ischemia-reperfusion injury via ecto-5Ј-nucleotidase activation might be mediated by an increase of adenosine, the main product of ecto-5Ј-nucleotidase. 11, 13, 22 However, other implicated mechanism of enhanced activation of the adenosine receptor (eg, increased receptor sensitivity) should be determined by future studies.
Possible Link Between Cardioprotection by Adenosine and NO
Previous studies support our present findings that statins rapidly activate the PI3-K/Akt pathway, 8, 9 and we obtained another preliminary finding that the cotreatment with N -nitro-L-arginine methyl ester (10 g · kg Ϫ1 · min Ϫ1 ) in the same manner as in protocol 1, which we confirmed did not affect baseline infarct size in the present model, 23 blunted the infarct limitation by pravastatin (36.8Ϯ4.1%, nϭ7), pitavastatin (39.9Ϯ3.9%, nϭ6), and cerivastatin (42.6Ϯ4.6%, nϭ5). Therefore, there is a possibility that ecto-5Ј-nucleotidase and NO act in series to cause statin-induced cardioprotection.
Although elucidation of a direct effect should be the focus of future studies, there are at least 2 lines of evidence to support the explanation that adenosine and NO synergistically caused infarct limitation in this study. First, NO directly exerts cardioprotection 24 : NO inhibits cell-to-cell adhesion, such as that between platelets 25 or between neutrophils and endothelial cells, 26, 27 by reducing expression of P-selectin, 27 E-selectin, and intercellular adhesion molecule-1, 28 which leads to attenuation of the inflammatory response 22, 24, 25 or protects against ischemia-reperfusion injury. [25] [26] [27] [28] In addition, NO is reported to inhibit caspase-3 activity and to block apoptosis of cardiac myocytes. 29 On the other hand, adenosine also rescues injured myocardium through activating adenosine receptors. 13,30 -32 Either administration of adenosine or enhancement of endogenous adenosine release during reperfusion after sustained ischemia limits infarct size. 13, 17 We and others have shown that (1) adenosine receptor (A 1 and A 2 ) activation improves contractile dysfunction after reperfusion, 14 (2) inhibition of norepinephrine release from the presynaptic vesicles and attenuation of calcium influx occur through the A 1 receptor and the coupled inhibitory G protein, 33, 34 (3) inhibition of platelet aggregation and leukocyte activation occurs through the A 2 receptor and the coupled stimulatory G protein, 34 -36 and (4) activation of extracellular signal-regulated kinase, one of the reperfusion injury survival kinase pathways, 37 takes place during reperfusion through the A 3 receptor. 38 Therefore, either adenosine or NO similarly and potentially protects injured myocardium through multiple pathways.
Second, recent articles have shown that either adenosine 38 -40 or NO 41 can reactivate PI3-K downstream. However, increasing the production of both agents is known to negatively regulate further increases of production of these molecules, 42, 43 suggesting the requirement of both pathways to confer sufficient cardioprotection in the physiological system. Taking all of these together, it is likely that adenosine and NO synergistically confer the statin-derived immediate cardioprotection shown in this study.
In conclusion, our findings suggest the cellular mechanism by which statins attenuate myocardial injury, which may indicate the possibility of acute protective therapies for ischemia and associated myocardial stresses.
